Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction

The American Journal of Cardiology

Volumn 66, Issue 20, 1990, Pages 1412-1417

  Bleich, Stanley D ^a,b,c,d,e   Nichols, Timothy C ^a,b,c,d,e   Schumacher, Richard R ^a,b,c,d,e   Cooke, David H ^a,b,c,d,e   Tate, David A ^a,b,c,d,e   Teichman, Sam L ^a,b,c,d,e  

^a TULANE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c METHODIST HOSPITAL   (United States)

^d ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^e GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; HEPARIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

COMPARATIVE STUDY; CORONARY ANGIOGRAPHY; CORONARY VESSELS; FEMALE; HEPARIN; HUMAN; MALE; MIDDLE AGE; MYOCARDIAL INFARCTION; PILOT PROJECTS; SUPPORT, NON-U.S. GOV'T; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR PATENCY;

EID: 0025687989     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9149(90)90525-6     Document Type: Article

References (43)

1. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction
2. Antithrombotic therapy for acute myocardial infarction: mechanisms and prevention of deep venous, left ventricular, and coronary artery thromboembolism
3. Antithrombotic therapy in cardiac disease: an emerging approach based on pathogenesis and risk
4. Factors influencing reocclusion after coronary thrombolysis for acute myocardial infarction
5. Rethrombosis after reperfusion with streptokinase: importance of geometry of residual lesions
6. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction
7. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction
8. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian study of early thrombolysis (ASSET)
9. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM) mortality morbidity and infarct size at 21 days
10. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial
11. Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: effects on infarct size and left ventricular function
12. TAMI-5: a randomized trial of combination thrombolytic therapy and immediate cardiac catheterization (abstr)
13. Randomised, double-blind trial of recombinant prourokinase against streptokinase in acute myocardial infarction
14. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction
15. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase
16. Exact significance testing for ordered categorical data
17. Myocardial reperfusion: is it ever too late?
18. Randomized trial of intravenous streptokinase oral aspirin both or neither among 17187 cases of suspected acute myocardial infarction ISIS-2
19. Late thrombolytic therapy preserves left ventricular function in patients with collateralized total coronary occlusion: primary end point findings on the Second Mount Sinai-New York University Reperfusion Trial
20. Effectiveness of intravenous thrombolytic therapy in acute myocardial infarction
21. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion
22. Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate
23. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction
24. Coronary perfusion during acute myocardial infarction with a combined therapy of coronary angioplasty and high-dose intravenous streptokinase
25. Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase
26. Thrombolytic therapy for patients with acute myocardial infarction
27. A new thrombolytic regimen for acute myocardial infarction using combination half dose tissue-type plasminogen activator with full dose streptokinase: a pilot study
28. Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in acute myocardial infarction
29. Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator: correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction
30. Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction
31. Randomized factorial trial of high-dose intravenous streptokinase or oral aspirin and of intravenous heparin in acute myocardial infarction ISIS (International Studies of Infarct Survival) pilot study
32. Hemorrhage vs. rethrombosis after thrombolysis for acute myocardial infarction
33. Role of heparin after intravenous thrombolytic therapy for acute myocardial infarction
34. Heparin and infarct coronary artery patency after streptokinase in acute myocardial infarction
35. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction
36. Effects of intracoronary streptokinase and intracoronary nitroglycerin infusion on coronary angiographie patterns and mortality in patients with acute myocardial infarction
37. A randomized comparison of oral aspirin/dipyridamole versus intravenous heparin after rt-PA for acute myocardial infarction (abstr)
38. A randomized pilot trial of brief versus prolonged heparin after successful reperfusion in acute myocardial infarction
39. Heparin versus aspirin after recombinant tissue plasminogen activator therapy in myocardial infarction a randomized trial (abstr)
40. Thrombolysis in Myocardial Infarction (TIMI) Trial-Phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase